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The human genetic basis of tuberculosis (TB) has long remained
elusive. We recently reported a high level of enrichment in
homozygosity for the common TYK2 P1104A variant in a heteroge-
neous cohort of patients with TB from non-European countries in
which TB is endemic. This variant is homozygous in∼1/600 Europeans
and ∼1/5,000 people from other countries outside East Asia and sub-
Saharan Africa. We report a study of this variant in the UK Biobank
cohort. The frequency of P1104A homozygotes was much higher in
patients with TB (6/620, 1%) than in controls (228/114,473, 0.2%),
with an odds ratio (OR) adjusted for ancestry of 5.0 [95% confidence
interval (CI): 1.96–10.31, P= 2× 10−3]. Conversely, we did not observe
enrichment for P1104A heterozygosity, or for TYK2 I684S or V362F
homozygosity or heterozygosity. Moreover, it is unlikely that more
than 10% of controls were infectedwithMycobacterium tuberculosis,
as 97% were of European genetic ancestry, born between 1939 and
1970, and resided in the United Kingdom. Had all of them been in-
fected, the OR for developing TB upon infection would be higher.
These findings suggest that homozygosity for TYK2 P1104A may ac-
count for ∼1% of TB cases in Europeans.
tuberculosis | TYK2 | monogenic | immunodeficiency | IFN-γ
Tuberculosis (TB) remains a major global public healthproblem. About a quarter of the world’s population is in-
of Europe in which this disease is endemic, relative to ancestry-
adjusted controls, with an odds ratio (OR) of 89.3 (95% CI,
14.7–1,725, P = 8.37 × 10−8) (24). Homozygosity for P1104A is
also a genetic etiology of MSMD, albeit with much lower esti-
mated penetrance (0.05%, everyone being exposed to poorly
virulent mycobacteria) than for TB (80%, upon infection with
M. tuberculosis) (24). Homozygosity for this allele had pre-
viously been shown to strongly protect against a variety of in-
flammatory conditions (25). The P1104A TYK2 protein can be
phosphorylated but remains catalytically inactive, resulting in a
selective impairment of the IL-23–dependent induction of IFN-
γ (24, 26). As many as 1/600 Europeans and ∼1/5,000 individ-
uals outside of East Asia and sub-Saharan Africa are homozy-
gous for P1104A (24). The frequency of this variant appears to
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fected with Mycobacterium tuberculosis (1, 2), resulting in ∼10 
million new cases and 1.6 million deaths worldwide in 2017 (3). 
Nevertheless, only ∼5% of infected individuals develop active 
TB in their lifetime (1, 4). Abundant evidence for the existence 
of a genetic component of TB in humans has accumulated from 
classic genetics studies performed from the turn of the 20th 
century onward, but its molecular architecture has long remained 
elusive (5–9). From 1996 onward, single-gene inborn errors of 
IFN-γ immunity have been found to underlie Mendelian sus-
ceptibility to mycobacterial disease (MSMD), which is character-
ized by severe disease caused by poorly virulent mycobacteria 
(bacillus Calmette–Guérin vaccines and environmental mycobac-
teria) (10–15). The clinical penetrance for MSMD depends on the 
genetic etiology and is inversely correlated with the levels of re-
sidual IFN-γ immunity (16). From 2001 onward, autosomal re-
cessive interleukin-12 receptor β1 (IL-12Rβ1) and tyrosine kinase 
2 (TYK2) deficiencies have also been identified in children with 
severe TB and without MSMD (17–23). These two deficiencies
impair both the IL-12– and IL-23–dependent production of IFN-γ. 
They are caused by very rare (minor allele frequency, MAF <5 × 
10−5 worldwide) or private loss-of-function alleles.
We recently discovered a strong enrichment in homozygosity 
for the common TYK2 missense variant P1104A in a genetically 
heterogeneous cohort of patients with TB from countries outside
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are shown in Fig. 1. More than 97% of these UK Biobank
participants, including all 234 P1104A homozygotes, are of Eu-
ropean ancestry according to this PCA. This finding is consistent
with the self-identification of 91% of the participants as British,
2% as Irish, and 4% as having another “white” ethnic back-
ground, as defined in field #21000 of the UK Biobank resource.
The remaining 3% of individuals, who declared themselves to be
of non-European or mixed ethnic background (Table 2), clus-
tered with the other major worldwide ethnic groups present in
the 1KG database (Fig. 1). Among the 234 P1104A homozy-
gotes, 212 controls and 5 TB patients claimed to be of British
origin, 4 controls and the sixth TB patient declared themselves to
be Irish, and the remaining 12 controls were of other white an-
cestries. We thus performed the association analysis by logistic
regression with adjustment for the first three principal compo-
nents of the PCA (24, 28). The results were very close to those of
the unadjusted analysis, with an OR for developing TB of 5.0
(1.96–10.31, P = 2 × 10−3) in P1104A homozygotes. No signifi-
cant enrichment was observed for P1104A heterozygotes, and
the other two common TYK2 alleles tested did not differ sig-
nificantly in frequency between the cases and controls (Table 1).
Finally, as familial relationships have been reported in the UK
Biobank cohort, we searched for all pairs of individuals pre-
senting evidence of relatedness, whether first-degree relatives or
monozygous twins. In total, 2,282 pairs were identified, including
26 cases without P1104A homozygosity and 4,338 controls, in-
cluding 7 homozygotes. We thus performed the association
analysis excluding these 4,364 individuals, and obtained very
similar results [OR = 5.07 (95% CI: 1.99–10.48); P = 1.8 × 10−3].
Collectively, these findings establish that homozygosity for the
TYK2 P1104A variant is a strong risk factor for TB in the pop-
ulation of European descent living in the United Kingdom.
Physician-diagnosed TB (#22137) is not the only TB-related
field in the UK Biobank resource. Data on hospital episode
statistics (#41202 and #41204), with International Classification
Table 1. Distribution of P1104A, I684S, and V362F TYK2 variants among cases and controls
and OR estimation for the dominant and recessive models of inheritance
OR, 95% CI*
Variant Genotype Cases, % Controls, % Dom Dom, adj Rec Rec, adj
P1104A GG 567 (91) 104,038 (91) 0.93 0.94 4.90 5.00
CG 47 (8) 10,207 (9) (0.69–1.22) (0.71–1.24) (1.93–10.10) (1.96–10.31)
CC 6 (1) 228 (0.2) P = 0.62 P = 0.71 P = 0.002 P = 0.002
I684S AA 525 (82) 96,158 (82) 1.01 1.03 0.89 0.82
CA 113 (18) 20,463 (18) (0.82–1.22) (0.84–1.25) (0.32–1.92) (0.32–1.96)
CC 5 (0.8) 1,028 (0.9) P = 0.96 P = 0.80 P = 0.79 P = 0.90
V362F CC 318 (49) 60,050 (51) 1.07 1.06 1.01 1.00
AC 275 (43) 48,434 (41) (0.91–1.25) (0.91–1.24) (0.75–1.33) (0.74–1.31)
AA 53 (8) 9,580 (8) P = 0.41 P = 0.43 P = 0.93 P = 0.97
Data were retrieved from the UK Biobank genotyped resource.
*Logistic regression was used to obtain ORs and P values (using a likelihood ratio test), and the first three
principal components of the PCA were added for the adjusted (adj) ORs and P values.
Table 2. Self-reported ethnic background of 115,093 P1104A
genotyped individuals of the UK Biobank database with doctor–
TB-diagnosed information
Ethnic background
Cases, %,
n = 620
Controls, %,
n = 114,473
Total, %,
n = 115,093
British 537 (87) 104,752 (91) 105,289 (91)
Irish 25 (4) 2,518 (2) 2,543 (2)
Other white 27 (4) 4,039 (4) 4,066 (4)
Other 31 (5) 3,128 (3) 3,159 (3)
have decreased in Europe over the last 4,000 y, perhaps attesting 
to purging by endemic TB (24). We hypothesized that homozygosity 
for this variant might underlie TB in a genetically homogeneous 
European population, and we tested this hypothesis by analyzing the 
UK Biobank resource.
Results
The UK Biobank is a prospective cohort of ∼500,000 volunteers 
between the ages of 40 and 69 y at recruitment, enrolled between 
2006 and 2010, from across the United Kingdom (UK) (27). We 
retrieved genome-wide genotyping data for all participants, to-
gether with TB-related phenotype information. Specifically, we 
used the most relevant field of the resource (#22137), providing 
“doctor-diagnosed” TB information for 121,284 participants in a 
binary format. In total, 654 of these individuals were confirmed 
as TB cases (code 1), whereas the other 120,630 individuals were 
not (code 0). These nontuberculous individuals were used as 
controls for subsequent analyses. The TYK2 P1104A variant 
(rs34536443) was genotyped in 620 of these cases and 114,473 of 
these controls. There was a slight excess of females among both 
cases (sex ratio male/female = 0.83) and controls (0.80), con-
sistent with the demographics of the entire UK Biobank cohort 
(0.84) (SI Appendix, Table S1). Mean age at recruitment was 56.5 y 
(SD = 7.7) for controls and 61.1 y (SD = 6.5) for patients with 
TB, who had a mean age of 18.5 y (SD = 16.0) at TB onset. The 
MAF of P1104A was 4.7% in controls (10,663/228,946 alleles), 
and a total of 234 individuals (234/115,093, 0.2%) were homo-
zygous for P1104A. The frequency of P1104A homozygotes was 
much higher in patients with TB (6/620 = 0.97%) than in con-
trols (228/114,473, 0.2%) [OR = 4.90 (95% CI: 1.93–10.10); P = 
2 × 10−3] (Table 1). TB onset occurred before the age of 15 y in 
three of the six homozygous patients (two born in 1944 and an-
other in 1946), and after the age of 50 y in the others (born in years 
1943, 1944, and 1946) (SI Appendix, Table S1). Heterozygous 
carriers of P1104A, used as controls, were evenly distributed be-
tween the two groups (Table 1). Moreover, no association with TB 
was observed with the other two common TYK2 missense variants 
genotyped, I684S and V362F, in the heterozygous, homozygous 
(Table 1), or compound heterozygous with P1104A states (P = 
0.82 and P = 0.71, respectively). These findings suggest that ho-
mozygosity for P1104A is a strong risk factor for TB in the United 
Kingdom, possibly accounting for as many as 1% of TB cases.
The participants in the UK Biobank cohort have various 
ethnic origins, but most are of British European descent (27). 
We conducted a principal component analysis (PCA) on the 
115,093 participants from this cohort and the 2,504 unrelated 
individuals of the “1000 Genome project” (1KG) database. The 
resulting PCA and the distribution of P1104A 
homozygotes
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of Diseases (ICD)-10 coded diagnosis information, are available
for patients of the UK Biobank database hospitalized after 1996.
A total of 47 TB-related ICD-10 codes for main or secondary
diagnoses are reported in at least one individual, aggregating to a
total of 312 individuals, with only 9 of these codes, in 57 indi-
viduals, including bacteriologically and/or histologically con-
firmed TB (SI Appendix, Table S2). Among the 312 individuals,
18 (including 6 with confirmed TB) also had physician-diagnosed
TB. This poor correlation is explained by the fact that 581 (89%)
physician-diagnosed TB cases occurred before 1996 (SI Appen-
dix, Fig. S1), before ICD-10 coding. An additional 20 ICD-10 TB
individuals (1 confirmed) belong in the 120,630 individuals with a
0 physician-diagnosis TB code (no TB), representing a proportion
of 0.02%, consistent with a low misclassification rate among our
controls. Finally, the remaining 274 individuals (50 confirmed)
belong in the 381,254 individuals without physician-diagnosed TB
information. Importantly, 164 (44%) of the 294 ICD-10 TB cases
(33% of the confirmed TB) that do not overlap with physician-
diagnosed TB cases have non-European ancestries, whereas a
total of only 146 (36 confirmed) were of British origin (SI Ap-
pendix, Table S3). Accordingly, none of the ICD-10 TB cases were
homozygous for the P1104A allele. Another TB-related field
extracted from the “Non-cancer illness code, self-reported
field” (#20002) was “self-reported TB,” adding up to a total
of 2,629 patients. We noted a very poor overlap with the other
TB-related fields, as only 308 (47%) of 654 physician-diagnosed
TB and 101 (32%) of 312 ICD-10 TB (35% for confirmed) had
self-reported TB. This is consistent with the poor self-reported
stroke information in the UK Biobank (29). Overall, the physician-
TB diagnosed field is the most reliable TB information available. The
654 TB cases have a reported age at onset, and a specific number of
120,630 individuals have an entered 0 code (no TB) in this field.
The UK Biobank individuals of European ancestry were born
between 1939 and 1970, when the mean annual incidence of TB
was declining from ∼75 per 100,000 in the 1950s to less than 20
per 100,000 in the 1970s (30). The prevalence of TB infection is
not known for the controls enrolled in the UK Biobank, but it
was reported to be below 10%, according to IFN-gamma release
assays, in other individuals at higher risk of exposure to M. tu-
berculosis living in the United Kingdom, such as nurses (31) and
prisoners (32). The prevalence of TB infection was found to be
6.9% in prisoners over the age of 45 y (32). These findings are
consistent with the lower annual incidence of TB in the UK-born
population, which was 3.2 per 100,000 in 2016, than in the non–
UK-born population, which was 49.4 per 100,000, giving an
overall incidence of 10.2 per 100,000 (33). All these observations
indicate that the vast majority (>90%) of UK Biobank controls
of European ancestry living in the United Kingdom are unlikely
to have been exposed to and infected with M. tuberculosis. As
noninfected controls are not at risk for developing TB, the
previously calculated OR for developing TB for P1104A homo-
zygotes is a major underestimation of the true risk of TB upon
infection. We thus simulated the distribution of P1104A homo-
zygotes in the control group assuming that all individuals were
infected. We conservatively estimated the probability of infected
individuals not homozygous for P1104A developing TB at 5% in
the general population. In our previous study, we used this
general TB risk value, together with the observed OR for TB
development in P1104A subjects to estimate the probability of
P1104A homozygotes developing TB upon infection, i.e., the
penetrance (SI Appendix, Supplementary Information Text); we
obtained an estimate for this penetrance of 82% (44–99%) (24).
We therefore removed from the control group the proportion of
individuals who would have developed TB upon infection: 5% of
those not homozygous and a proportion of homozygotes ranging
from 40 to 80% (a conservative range of values with respect to
penetrance estimates). The resulting ORs for developing TB
upon infection are shown in SI Appendix, Fig. S2, and are esti-
mated at 7.7 and 23.0 for a penetrance of 40% and 80%, re-
spectively. In other words, compared with the global risk of 5%,
one can estimate the relative risk of TYK2 homozygotes de-
veloping TB between 8 (for a penetrance of 40%) and 16 (80%).
Despite the use of crude estimates for this simulation, it dem-
onstrates a very strong effect of P1104A homozygosity on the risk
of TB upon infection.
Another point of interest is the proportion of TB cases ho-
mozygous for P1104A. In our previous study, the seven patients
homozygous for P1104A originated from Brazil, Chile, Algeria,
Morocco, and Turkey, countries with an annual incidence of TB
ranging from 17 per 100,000 (Chile) to 99 per 100,000 (Mo-
rocco). Based on a mean MAF for P1104A of ∼1.4% in these
countries, and on the probabilities of developing TB upon in-
fection for homozygotes and nonhomozygotes, as described
above, we estimated that ∼0.33% (95% CI: 0.17–0.40%) of TB
cases might be due to homozygosity for P1104A (24). Here, we
obtained a more reliable estimate by focusing on a population
with a homogeneous European genetic background. For this
estimation, we used only the 589 TB cases and 111,345 controls
of self-reported British, Irish, and other white ancestries of the
UK Biobank cohort, corresponding to 97% of our initial sample
(Table 2). P1104A homozygotes accounted for 1.02% of
TB cases of European origin (6/589), but only 0.2% of controls
(228/111,345). The overall MAF of P1104A in European controls
was 4.7%, consistent with the value obtained for the remaining
357,710 UK Biobank individuals without TB information (4.5%),
slightly higher than for Europeans in the gnomAD database
(4%) (https://gnomad.broadinstitute.org/contact). Overall, these
results indicate that homozygosity for the P1104A TYK2 allele is a
Fig. 1. PCA of the UK Biobank individuals and the 1000 Genome project
subjects. The figure shows the PCA (PC1 vs. PC2) conducted on genotyping
data for 115,093 individuals with doctor-diagnosed coding from the UK
Biobank cohort and 2,504 subjects of the 1000 Genome (1KG) project. The
percentages of variance explained by PC1 and PC2 are shown in parentheses.
Colored crosses are used to represent the five major ethnic groups from the
1KG project: Africans (AFR, violet), Americans (AMR, light green), East Asians
(EAS, orange), Europeans (EUR, dark green), and South Asians (SAS, blue).
Light-gray circles are used to represent the individuals from the UK Biobank
cohort. Homozygous carriers of the TYK2 P1104A allele are indicated by red
(cases) or dark-gray (controls) diamonds.
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common monogenic etiology of TB, accounting for about 1% of
TB cases in Britain and, by inference, probably in other pop-
ulations of European ancestry.
Discussion
We have shown that homozygosity for TYK2 P1104A confers a
strong predisposition to TB in individuals of European ancestry
originating from and living in the United Kingdom after World
War II. This result is consistent with our previous findings for a
genetically heterogeneous cohort of patients with TB from various
non-European countries in which TB is endemic (24). The results
presented here were obtained using a population of homogeneous
ancestry exposed to similar environmental pressures, with more
than 97% of cases and controls having European ancestry, and all
living in the United Kingdom between 1939 and 2010. Impor-
tantly, the participants of this study were all living in a country of
low endemicity for TB, as it is unlikely that more than 10% of
Britons after World War II were infected by M. tuberculosis. This
implies that the estimated OR of P1104A homozygotes developing
TB upon infection (OR = 5) is underestimated. It is more likely to
be >10, as shown by the data for the infected control simulation,
corresponding to a lifetime risk of TB between 40 and 80%. This
OR is higher than those reported for the few SNPs identified by
genome-wide association studies (GWAS) in TB (34–46). These
12 GWAS did not detect the effect of P1104A, as they did not
report testing a recessive model. This is also the case for the UK
Biobank GWAS conducted on the self-reported TB phenotype
accessible in Gene Atlas (47). In addition, most of these studies, in
particular the 10 studies in Latin America (n = 1), Africa (n = 5),
and Asia (n = 4), for which the frequency of the P1104A allele is
lower, would have been underpowered.
We performed GWAS for the “doctor-diagnosed” TB phe-
notype in the UK Biobank data under a recessive model and
P1104A (P = 2 × 10−3) remained below the genome-wide signif-
icance threshold (5 × 10−8) (SI Appendix, Fig. S3). A limitation of
our study is the relatively small number of physician-diagnosed TB
cases (n = 620). Assuming 1% of homozygotes among cases and
0.2% among controls in a balanced case-control study, 5,550 cases
and 5,550 controls would be needed to reach a genome-wide
significant P value of 5 × 10−8. It will be important to test
whether homozygosity for P1104A is associated with TB in other,
larger cohorts of European ancestry. While no variants reached a
P value < 2 × 10−6 in our GWAS, 121 variants with a more sig-
nificant P value than P1104A (<2 × 10−3) and with an MAF > 2%
gave ORs higher than 5, suggesting that there may be other recessive
etiologies of TB in this cohort. Interestingly, GWAS performed on
other, larger population samples for phenotypes other than TB have
shown that homozygosity for TYK2 P1104A has a strong protective
effect (ORs ranging from 0.1 to 0.3) against various auto-
inflammatory or autoimmune conditions (25, 48–54). In light of
these results, the potential pharmacological benefits of TYK2 in-
hibitors for treating autoinflammatory or autoimmune conditions
are currently being evaluated (55–57). Our findings indicate that if
such treatments were to be introduced into widespread use, then it
would be important to assess the risk of TB before and during
treatment, as is currently done for anti-TNF immunotherapy (58).
Homozygosity for the TYK2 P1104A variant apparently un-
derlies a sizable proportion of TB cases, perhaps accounting for
∼1% of TB cases in Europeans and ∼0.33% of cases in most
other regions of the world (i.e., outside Europe, sub-Saharan
Africa, and Eastern Asia). While this small percentage is
estimated from a small number of patients, in this (95% CI: 0.2–
1.8%) and in our previous study (95% CI: 0.17–0.40%, ref. 24), it
corresponds to millions of individuals over the last 10,000 y. An
estimate of 1 billion deaths from TB in Europe over the last
2,000 y (SI Appendix, Supplementary Information Text; refs. 59,
60) would imply that about 10 million of these people died due
to TYK2 P1104A homozygosity. Future studies based on an-
cient DNA time transects should attempt to track the allele
frequency trajectories of the P1104A allele across time and in
different regions of the world, following up our initial observa-
tions for a small population of ancient Europeans (24, 61). Our
findings suggested that the frequency of P1104A had decreased
from 9 to 4.2% over the last 4,000 y in Europe, which was con-
sistent with a purge operated by TB (24). These studies should be
interpreted in light of other population-based studies of the
contribution of P1104A homozygosity to the development of TB
across modern-day human populations. The lower frequency of
P1104A in populations of non-European ancestry, including in
particular its very low frequency in East Asia and sub-Saharan
Africa, will require unusually large population-based studies.
A large number of P1104A-related TB cases would have major
implications for the prevention and treatment of TB. It should
make it easier to target individuals at high risk of TB when de-
fining optimal cohorts for trials of TB candidate vaccines. Indeed,
vaccination strategies should aim at protecting the 5% of indi-
viduals who are not naturally, genetically resistant to M. tubercu-
losis. Genetic testing for this variant may also be warranted before
travel to countries highly endemic for TB. The vast majority of
P1104A homozygotes living in the most developed countries are
asymptomatic, as they have not been exposed to M. tuberculosis
and the penetrance for MSMD is very low (24). The diagnosis of
P1104A homozygosity in patients with TB could also pave the way
for genetic counseling in their families. Moreover, injections of
recombinant IFN-γ would probably be beneficial in these patients,
as in patients with IL-12Rβ1 deficiency (15, 62, 63). This is of
particular importance in the current context of increasing drug
resistance in M. tuberculosis strains (64–66). Finally, the notion
that 0.5–1% of TB is autosomal recessive and accounted for by
homozygosity for a common TYK2 variant has far-reaching im-
plications for the genetic study of TB and other common, severe
infectious diseases (67, 68). This discovery further blurs the di-
chotomy between rare monogenic etiologies (rare variants with a
large effect) and common risk factors (common variants with a
modest effect) (69–76). It should prompt searches for other
monogenic but common causes of TB and other severe infections.
ACKNOWLEDGMENTS. This research was performed with the UK Biobank
Resource, under application number 46216. We thank both branches of the
Laboratory of Human Genetics of Infectious Diseases; Philippe Gros, Lennart
Hammarström, and Carl Nathan for helpful discussions and support; and
Y. Nemirovskaya, M. Woollett, C. Patissier, C. Desvallées, and D. Papandrea for
administrative support. The Laboratory of Human Genetics of Infectious
Diseases was supported in part by grants from the French National Agency
for Research (ANR) under the “Investissement d’avenir” program (Grant
ANR-10-IAHU-01); the “Deciphering tuberculosis pathogenesis by identifying
single-gene inborn errors of immunity” (TBPATHGEN) project (Grant ANR-
14-CE14-0007-01); the Integrative Biology of Emerging Infectious Diseases
Laboratory of Excellence (Grant ANR-10-LABX-62-IBEID); the European Re-
search Council (ERC) (Grant ERC-2010-AdG-268777); the SCOR Corporate
Foundation for Science; the St. Giles Foundation; the National Center for
Research Resources and the National Center for Advancing Sciences; Na-
tional Institutes of Health Grant UL1TR001866; the National Institute of
Allergy and Infectious Diseases Grants 5R01AI089970, 5R37AI095983,
5U01AI088685, and 5U19AI111143; and The Rockefeller University.
1. Esmail H, Barry CE, 3rd, Young DB, Wilkinson RJ (2014) The ongoing challenge of
latent tuberculosis. Philos Trans R Soc Lond B Biol Sci 369:20130437.
2. Houben RMGJ, Dodd PJ (2016) The global burden of latent tuberculosis infection: A
re-estimation using mathematical modelling. PLoS Med 13:e1002152.
3. WHO (2018) Global tuberculosis report 2018. Available at https://www.who.int/tb/
publications/global_report/en/. Accessed March 1, 2019.
4. Borgdorff MW, et al. (2011) The incubation period distribution of tuberculosis esti-
mated with a molecular epidemiological approach. Int J Epidemiol 40:964–970.
5. Puffer R (1944) Familial Susceptibility to Tuberculosis: Its Importance as a Public
Health Problem (Harvard Univ Press, Cambridge, MA).
6. Abel L, et al. (2018) Genetics of human susceptibility to active and latent tuberculosis:
Present knowledge and future perspectives. Lancet Infect Dis 18:e64–e75.
4 of  5  | Kerner et al.
7. Kallmann FJ, Reisner D (1943) Twin studies on the significance of genetic factors in
tuberculosis. Am Rev Tuberc 47:549–571.
8. von Verschuer F (1939) Twin research from the time of Francis Galton to the present-
day. Proc R Soc Lond B Biol Sci 128:62–81.
9. Pearson K (1909) Discussion on the influence of heredity on disease, with special
reference to tuberculosis, cancer, and diseases of the nervous system: Introductory
address. Proc R Soc Med 2:54–60.
10. Altare F, et al. (1998) Impairment of mycobacterial immunity in human interleukin-12
receptor deficiency. Science 280:1432–1435.
11. Altare F, et al. (1998) Inherited interleukin 12 deficiency in a child with bacille Calmette-
Guérin and Salmonella enteritidis disseminated infection. J Clin Invest 102:2035–2040.
12. de Jong R, et al. (1998) Severe mycobacterial and Salmonella infections in interleukin-
12 receptor-deficient patients. Science 280:1435–1438.
13. Jouanguy E, et al. (1996) Interferon-gamma-receptor deficiency in an infant with fatal
bacille Calmette-Guérin infection. N Engl J Med 335:1956–1961.
14. Newport MJ, et al. (1996) A mutation in the interferon-gamma-receptor gene and
susceptibility to mycobacterial infection. N Engl J Med 335:1941–1949.
15. Bustamante J, Boisson-Dupuis S, Abel L, Casanova J-L (2014) Mendelian susceptibility
to mycobacterial disease: Genetic, immunological, and clinical features of inborn
errors of IFN-γ immunity. Semin Immunol 26:454–470.
16. Dupuis S, et al. (2000) Human interferon-gamma-mediated immunity is a genetically
controlled continuous trait that determines the outcome of mycobacterial invasion.
Immunol Rev 178:129–137.
17. Altare F, et al. (2001) Interleukin-12 receptor beta1 deficiency in a patient with ab-
dominal tuberculosis. J Infect Dis 184:231–236.
18. Boisson-Dupuis S, et al. (2011) IL-12Rβ1 deficiency in two of fifty children with severe
tuberculosis from Iran, Morocco, and Turkey. PLoS One 6:e18524.
19. Boisson-Dupuis S, et al. (2015) Inherited and acquired immunodeficiencies underlying
tuberculosis in childhood. Immunol Rev 264:103–120.
20. Caragol I, et al. (2003) Clinical tuberculosis in 2 of 3 siblings with interleukin-12 re-
ceptor beta1 deficiency. Clin Infect Dis 37:302–306.
21. Kreins AY, et al. (2015) Human TYK2 deficiency: Mycobacterial and viral infections
without hyper-IgE syndrome. J Exp Med 212:1641–1662.
22. Ozbek N, et al. (2005) Interleukin-12 receptor beta 1 chain deficiency in a child with
disseminated tuberculosis. Clin Infect Dis 40:e55–e58.
23. Tabarsi P, et al. (2011) Lethal tuberculosis in a previously healthy adult with IL-12
receptor deficiency. J Clin Immunol 31:537–539.
24. Boisson-Dupuis S, et al. (2018) Tuberculosis and impaired IL-23-dependent IFN-γ immunity
in humans homozygous for a common TYK2 missense variant. Sci Immunol 3:eaau8714.
25. Dendrou CA, et al. (2016) Resolving TYK2 locus genotype-to-phenotype differences in
autoimmunity. Sci Transl Med 8:363ra149.
26. Martínez-Barricarte R, et al. (2018) Human IFN-γ immunity to mycobacteria is gov-
erned by both IL-12 and IL-23. Sci Immunol 3:eaau6759.
27. Bycroft C, et al. (2018) The UK Biobank resource with deep phenotyping and genomic
data. Nature 562:203–209.
28. Belkadi A, et al.; Exome/Array Consortium (2016) Whole-exome sequencing to ana-
lyze population structure, parental inbreeding, and familial linkage. Proc Natl Acad
Sci USA 113:6713–6718.
29. Woodfield R, Sudlow CL; UK Biobank Stroke Outcomes Group; UK Biobank Follow-up
and Outcomes Working Group (2015) Accuracy of patient self-report of stroke: A sys-
tematic review from the UK Biobank stroke outcomes group. PLoS One 10:e0137538.
30. Glaziou P, Floyd K, Raviglione M (2018) Trends in tuberculosis in the UK. Thorax 73:
702–703.
31. Khanna P, Nikolayevskyy V, Warburton F, Dobson E, Drobniewski F (2009) Rate of
latent tuberculosis infection detected by occupational health screening of nurses new
to a London teaching hospital. Infect Control Hosp Epidemiol 30:581–584.
32. Gray BJ, Perrett SE, Gudgeon B, Shankar AG (January 4, 2019) Investigating the
prevalence of latent Tuberculosis infection in a UK remand prison. J Public Health
(Oxf), 10.1093/pubmed/fdy219.
33. Public Health England (2017) Tuberculosis in England. Available at https://www.gov.uk/
government/organisations/public-health-england. Accessed October 24, 2017.
34. Schurz H, et al. (2019) A sex-stratified genome-wide association study of tuberculosis
using a multi-ethnic genotyping array. Front Genet 9:678.
35. Zheng R, et al. (2018) Genome-wide association study identifies two risk loci for tu-
berculosis in Han Chinese. Nat Commun 9:4072.
36. Qi H, et al. (2017) Discovery of susceptibility loci associated with tuberculosis in Han
Chinese. Hum Mol Genet 26:4752–4763.
37. Sobota RS, et al. (2016) A locus at 5q33.3 confers resistance to tuberculosis in highly
susceptible individuals. Am J Hum Genet 98:514–524.
38. Sveinbjornsson G, et al. (2016) HLA class II sequence variants influence tuberculosis
risk in populations of European ancestry. Nat Genet 48:318–322.
39. Grant AV, et al. (2016) A genome-wide association study of pulmonary tuberculosis in
Morocco. Hum Genet 135:299–307.
40. Curtis J, et al. (2015) Susceptibility to tuberculosis is associated with variants in the
ASAP1 gene encoding a regulator of dendritic cell migration. Nat Genet 47:523–527.
41. Chimusa ER, et al. (2014) Genome-wide association study of ancestry-specific TB risk in
the South African coloured population. Hum Mol Genet 23:796–809.
42. Mahasirimongkol S, et al. (2012) Genome-wide association studies of tuberculosis in
Asians identify distinct at-risk locus for young tuberculosis. J Hum Genet 57:363–367.
43. Png E, et al. (2012) A genome wide association study of pulmonary tuberculosis
susceptibility in Indonesians. BMC Med Genet 13:5.
44. Thye T, et al. (2012) Common variants at 11p13 are associated with susceptibility to
tuberculosis. Nat Genet 44:257–259.
45. Thye T, et al.; African TB Genetics Consortium; Wellcome Trust Case Control Con-
sortium (2010) Genome-wide association analyses identifies a susceptibility locus for
tuberculosis on chromosome 18q11.2. Nat Genet 42:739–741.
46. Luo Y, et al. (2018) Progression of recent Mycobacterium tuberculosis exposure to
active tuberculosis is a highly heritable complex trait driven by 3q23 in Peruvians.
bioRxiv:10.1101/401984. Preprint, posted August 28, 2018.
47. Canela-Xandri O, Rawlik K, Tenesa A (2018) An atlas of genetic associations in UK
Biobank. Nat Genet 50:1593–1599.
48. Diogo D, et al. (2015) TYK2 protein-coding variants protect against rheumatoid ar-
thritis and autoimmunity, with no evidence of major pleiotropic effects on non-
autoimmune complex traits. PLoS One 10:e0122271.
49. Cortes A, et al.; International Genetics of Ankylosing Spondylitis Consortium (IGAS);
Australo-Anglo-American Spondyloarthritis Consortium (TASC); Groupe Française
d’Etude Génétique des Spondylarthrites (GFEGS); Nord-Trøndelag Health Study
(HUNT); Spondyloarthritis Research Consortium of Canada (SPARCC); Wellcome Trust
Case Control Consortium 2 (WTCCC2) (2013) Identification of multiple risk variants for
ankylosing spondylitis through high-density genotyping of immune-related loci. Nat
Genet 45:730–738.
50. Beecham AH, et al.; International Multiple Sclerosis Genetics Consortium (IMSGC);
Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics
Consortium (IIBDGC) (2013) Analysis of immune-related loci identifies 48 new sus-
ceptibility variants for multiple sclerosis. Nat Genet 45:1353–1360.
51. Jostins L, et al.; International IBD Genetics Consortium (IIBDGC) (2012) Host-microbe
interactions have shaped the genetic architecture of inflammatory bowel disease.
Nature 491:119–124.
52. Tsoi LC, et al.; Collaborative Association Study of Psoriasis (CASP); Genetic Analysis of
Psoriasis Consortium; Psoriasis Association Genetics Extension; Wellcome Trust Case
Control Consortium 2 (2012) Identification of 15 new psoriasis susceptibility loci
highlights the role of innate immunity. Nat Genet 44:1341–1348.
53. Fodil N, Langlais D, Gros P (2016) Primary immunodeficiencies and inflammatory
disease: A growing genetic intersection. Trends Immunol 37:126–140.
54. Langlais D, Fodil N, Gros P (2017) Genetics of infectious and inflammatory diseases:
Overlapping discoveries from association and exome-sequencing studies. Annu Rev
Immunol 35:1–30.
55. Gadina M, et al. (2018) Translational and clinical advances in JAK-STAT biology: The
present and future of jakinibs. J Leukoc Biol 104:499–514.
56. He X, Chen X, Zhang H, Xie T, Ye X-Y (2019) Selective Tyk2 inhibitors as potential
therapeutic agents: A patent review (2015-2018). Expert Opin Ther Pat 29:137–149.
57. Papp K, et al. (2018) Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N
Engl J Med 379:1313–1321.
58. Kaya FO (2017) Anti-TNF treatment and tuberculosis. Austin J Pulm Respir Med 4:
1055.
59. Dubos RJ, Dubos J (1987) The White Plague: Tuberculosis, Man, and Society (Rutgers
Univ Press, New Brunswick, NJ).
60. Murray JF (2015) The Industrial Revolution and the decline in death rates from tu-
berculosis. Int J Tuberc Lung Dis 19:502–503.
61. Olalde I, et al. (2018) The Beaker phenomenon and the genomic transformation of
northwest Europe. Nature 555:190–196.
62. Fieschi C, et al. (2003) Low penetrance, broad resistance, and favorable outcome of
interleukin 12 receptor β1 deficiency: Medical and immunological implications. J Exp
Med 197:527–535.
63. Holland SM (2001) Immunotherapy of mycobacterial infections. Semin Respir Infect
16:47–59.
64. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C (2012) Totally drug-resistant tuber-
culosis in India. Clin Infect Dis 54:579–581.
65. Daley CL, Caminero JA (2018) Management of multidrug-resistant tuberculosis. Semin
Respir Crit Care Med 39:310–324.
66. Dheda K, et al. (2017) The epidemiology, pathogenesis, transmission, diagnosis, and
management of multidrug-resistant, extensively drug-resistant, and incurable tu-
berculosis. Lancet Respir Med, S2213-2600(17)30079-6.
67. Casanova J-L (2015) Human genetic basis of interindividual variability in the course of
infection. Proc Natl Acad Sci USA 112:E7118–E7127.
68. Casanova J-L (2015) Severe infectious diseases of childhood as monogenic inborn
errors of immunity. Proc Natl Acad Sci USA 112:E7128–E7137.
69. Cohen JC, Hobbs HH (2013) Genetics. Simple genetics for a complex disease. Science
340:689–690.
70. Chakravarti A, Clark AG, Mootha VK (2013) Distilling pathophysiology from complex
disease genetics. Cell 155:21–26.
71. Florez JC, Hirschhorn J, Altshuler D (2003) The inherited basis of diabetes mellitus:
Implications for the genetic analysis of complex traits. Annu Rev Genomics Hum
Genet 4:257–291.
72. Katsanis N (2016) The continuum of causality in human genetic disorders. Genome
Biol 17:233.
73. McLaren PJ, Carrington M (2015) The impact of host genetic variation on infection
with HIV-1. Nat Immunol 16:577–583.
74. McClellan J, King M-C (2010) Genetic heterogeneity in human disease. Cell 141:210–217.
75. Casanova J-L, Abel L (2002) Genetic dissection of immunity to mycobacteria: The
human model. Annu Rev Immunol 20:581–620.
76. Lifton RP (2004) Genetic dissection of human blood pressure variation: Common
pathways from rare phenotypes. Harvey Lect 100:71–101.
Kerner et al. 5
G
EN
ET
IC
S
